{"id":"532aa930-a185-580a-b8a8-3e5b324a380d","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-rat-methylated-product","predicate":"reported_relationship","statement":"Luteolin formed downstream of apigenin could undergo methylation to diosmetin in the rat metabolic study.","claim_class":"mechanistic","status":"source_recorded","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"049a3336-f1cd-57af-b0d7-9bf5fc198c19","mechanism_event_label":"Luteolin formed downstream of apigenin could undergo methylation to diosmetin in the rat metabolic study.","subject":{"id":"80472c4b-ecc2-52e3-a766-f8463294774f","slug":"luteolin","display_name":"Luteolin / 3′,4′,5,7-tetrahydroxyflavone","entity_type_key":"small_molecule"},"object":{"id":"bf4740f4-99fb-500c-94f8-381d5a49dbd9","slug":"diosmetin","display_name":"Diosmetin / 4′-O-methylluteolin","entity_type_key":"small_molecule"},"evidence_count":1,"mechanism_event":{"id":"049a3336-f1cd-57af-b0d7-9bf5fc198c19","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-rat-methylated-product-event","event_type":"biochemical_relationship","label":"Luteolin formed downstream of apigenin could undergo methylation to diosmetin in the rat metabolic study.","description":"### api-rat-methylated-product\n\nLuteolin formed downstream of apigenin could undergo methylation to diosmetin in the rat metabolic study.\nThis does not show that parent apigenin depletes SAM, that one COMT genotype benefits, or that circulating human methyl-donor pools fall.\nModel and exposure: Rat metabolism preparations; primary abstract.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Metabolism of apigenin by rat liver phase I and phase ii enzymes and by isolated perfused rat liver. | 2004 | https://pubmed.ncbi.nlm.nih.gov/14709621/ | https://doi.org/10.1124/dmd.32.1.58 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"80472c4b-ecc2-52e3-a766-f8463294774f","slug":"luteolin","display_name":"Luteolin / 3′,4′,5,7-tetrahydroxyflavone","entity_type_key":"small_molecule"},"role":"recorded factor","stoichiometry":null,"state_label":"as reported","sequence_order":0,"notes":""},{"entity":{"id":"bf4740f4-99fb-500c-94f8-381d5a49dbd9","slug":"diosmetin","display_name":"Diosmetin / 4′-O-methylluteolin","entity_type_key":"small_molecule"},"role":"measured outcome","stoichiometry":null,"state_label":"not_reported","sequence_order":1,"notes":""},{"entity":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"role":"upstream parent","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Rat metabolism preparations; primary abstract.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Luteolin formed downstream of apigenin could undergo methylation to diosmetin in the rat metabolic study.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Metabolism of apigenin by rat liver phase I and phase ii enzymes and by isolated perfused rat liver. | https://pubmed.ncbi.nlm.nih.gov/14709621/ | https://doi.org/10.1124/dmd.32.1.58","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-rat-methylated-product; This does not show that parent apigenin depletes SAM, that one COMT genotype benefits, or that circulating human methyl-donor pools fall.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"9272d90c-ea4c-5b91-9c81-fb4bf46fb553","evidence_kind":"source_excerpt","locator":"Lines 122-128","start_line":122,"end_line":128,"excerpt":"### api-rat-methylated-product\n\nLuteolin formed downstream of apigenin could undergo methylation to diosmetin in the rat metabolic study.\nThis does not show that parent apigenin depletes SAM, that one COMT genotype benefits, or that circulating human methyl-donor pools fall.\nModel and exposure: Rat metabolism preparations; primary abstract.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Metabolism of apigenin by rat liver phase I and phase ii enzymes and by isolated perfused rat liver. | 2004 | https://pubmed.ncbi.nlm.nih.gov/14709621/ | https://doi.org/10.1124/dmd.32.1.58 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","model_system":"Rat metabolism preparations; primary abstract.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}